Table 5. Cholesterol and Particle Number Goals of Therapy LDL Particle Number Targets
Cholesterol Targets (LDL-C and Non-HDL-C)
Risk Category
High Risk Moderate Low Riska
LDL-C1 (mg/dL)
clinical judgment) < 130
(may consider < 70 based on
< 100
clinical judgment) Ideal < 130
(may consider < 100 based on
Non-HDL-C1 (mg/dL)
(< 100 if LDL-C target of < 70 is selected)
< 130
(< 130 if LDL-C target of < 100 is selected)
< 160 Ideal < 160 Step 3: Laboratory Evaluation ÎFasting lipid profile, LDL particle number (measured apoB or NMR).
ÎAdditional testing as indicated to evaluate secondary causes of dyslipoproteinemia:
• Glycemic parameters: glucose, HbA1c ▶ Renal Functions: creatinine, cystatin-C, urine albumin • Hepatic function panel
ÎMay consider additional laboratory or noninvasive imaging studies to further assess CVD risk:
• Assessment of insulin resistance ▶ Lipoprotein insulin resistance score ▶ Insulin level (HOMA Score)
• Lp(a) • Inflammatory markers: ▶ hs-CRP
• Vitamin D3 • Homocysteine • Noninvasive imaging studies ▶ Coronary calcium score ▶ CIMT
▶ Lp-PLA2 ▶ Myeloperoxidase
NMR LDL-P2-4 (nmol/L)
clinical judgment) < 1,300
(may consider < 800 based on
< 1,000
< 1,000 based on clinical judgment)
(may consider Ideal < 1,300
a Ideal values recommended based on CHD event rates in prospective trials.1, 5 should be used in determining individual patient goals.
clinical judgment) < 100
(may consider < 70 based on
< 80
clinical judgment) Ideal < 100
(may consider < 80 based on
Clinical judgement
(NMR LDL-P or Measured Apo B)
Measured Apo B3, 4 (mg/dL)
11
